A randomized double-blind, placebo-controlled, multicenter;trial assessing the impact of lipoprotein (a) lowering with;TQJ230 on major cardiovascular events in patients with;established cardiovascular disease (HORIZON)
This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a). The primary objectives of this study is to demonstrate the superiority of TQJ230 compared to placebo in reducing the risk of expanded MACE (cardiovascular death, non-fatal MI, non-fatal stroke and urgent coronary re-vascularization requiring hospitalization) in 1) the overall study population with established CVD (Lp(a) ≥ 70 mg/dL) and/or 2) in a sub-population with established CVD and Lp(a) ≥ 90 mg/dL.
Cardiovascular Disease and Lipoprotein(a)
Clinics and Surgery Center (CSC)